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Costs and effectiveness of two models of school-entry visual acuity screening in 
the UK
Anna Horwooda,b, Deborah Lysonsb, Victoria Sandfordb, and Greg Richardsonb
aUniversity of Reading, Earley Gate, Reading; bRoyal Berkshire Hospital, Orthoptic Department, Royal Berkshire Hospital, Reading
ABSTRACT
Cost effectiveness of different visual screening modalities cannot be calculated without long-term 
outcome data. This paper reports detailed outcomes from a gold-standard UK recommended 
orthoptist-delivered screening (ODS) at 4–5 years in school, compared to a neighboring school- 
nurse delivered screening (SNDS), both feeding into the same treatment pathway. The target 
condition was reduced visual acuity (VA) of worse than logMAR 0.2 in either eye.
Available records from screening databases and hospital records were analyzed, comparing the 
two services wherever possible.
More screening data was available from the ODS. ODS: 5706 screened, 3.5% referred. False 
positives 6.5%, PPV 91.4%, sensitivity 97.9%, and specificity 99.8% for reduced VA. Cost per child 
with reduced vision detected £195.22, and per amblyope detected £683.28. The mean treatment 
cost per child with reduced VA was £331.68 and for amblyopia treatment was £458.65.
SNDS: 5630 screened and 3.8% referred (plus some referrals to local optometrists lost to follow 
up). False positives 34%, PPV 53.2%, sensitivity and specificity estimated as 89.3% and 98.67%. Costs 
to secondary services of false positives were seven times greater. The cost per child with confirmed 
reduced vision seen at the hospital was 46% more; and per amblyope detected was 39% more.
Outcomes for treatment post referral in both groups were similar and excellent. 86% of genuine 
referrals improved to within normal limits with glasses alone. Of 221 genuine referrals with final 
outcome data, all now have better than 0.2logMAR acuity in the better eye and only two (0.9%) 
have residual amblyopia in one eye worse than 0.4logMAR.
About 14–18% of children with reduced VA would have passed AAPOS photoscreening referral 
criteria.
An orthoptist-delivered single VA screen at 4–5 years is highly cost effective with good out-
comes. The main contributing factors to success appear to be training and experience in accurate 
VA testing, the opportunity to rescreen equivocal results, and monitoring, audit, and feedback of 
outcomes.
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Introduction
The United Kingdom National Screening 
Committee (UKNSC) recommends that beyond 
neonatal screening, the next child vision screening 
should be a linear visual acuity (VA) test in the 
first year of compulsory education at 4–5 years, 
delivered or led by orthoptists. 1
The EUscreen study2 is highlighting how cost 
effectiveness modeling of different screening modal-
ities is severely hampered by lack of reports of long- 
term costs and outcomes, in comparison to shorter- 
term outcomes such as positive predictive values 
(PPVs) for a specific diagnosis (for reviews see.3,4) 
Even if data are audited locally, they are not shared.
Cost effectiveness is particularly important for 
publicly funded health services paying for the 
whole patient journey from detection to discharge. 
Low screening costs may not be matched by equally 
cost-effective follow-up, and outcomes may differ 
between different screening timings and methods. 
A particular issue in children’s vision screening is 
comparative costs of early automated photoscreen-
ing for refractive risk factors for treatable reduced 
vision and amblyopia, versus later visual acuity 
(VA) testing by a skilled tester which detects actual 
reduction in vision. Because more children will 
have risk factors than will be amblyopic, low-cost 
photoscreening5 might be less cost effective in the 
long term due to more, less precise referrals, and 
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more expensive visits to secondary services, with-
out clear evidence of better outcomes at 
a population level.4
This paper describes a long-term audit of out-
comes and costs associated with referrals from two 
established neighboring school-entry vision screen-
ing services in southern England from one 
academic year, one following national guidelines 
more closely than the other. Both populations are 
majority White British, but with significant and 
similar numbers of ethnic diversity including 
South Asian, Afro-Caribbean and Eastern 
European families (see Supplemental File) in both 
areas. There are some areas of socio-economic 
deprivation in both areas, but the whole region is 
relatively economically prosperous.
Both services test 4–5-year-old children in their 
first year of compulsory school, use the same vali-
dated linear logMAR test (the 3 m Sonksen test6 
with a pass threshold of 0.2logMAR in either eye). 
They feed into the same healthcare provider man-
aged by the same National Health Service (NHS) 
team, using common treatment protocols free at 
point of delivery, and common records software. 
All treatment of uncomplicated amblyopia and 
refractive error is carried out by a joint orthoptist/ 
optometrist service managed by orthoptists. The 
receiving hospital trust covers the whole county, 
so few referrals go elsewhere, and local optometrists 
generally refer any amblyopic child to hospital.
Orthoptist delivered screening (ODS)
This service is run by the orthoptic service and 
delivered by five experienced orthoptists. Each 
orthoptist travels to many schools in the area to 
test large numbers of children (60–70 (two 
classes) per session, >1000 per year), screening 
once or twice a week, interleaved with hospital 
practice. Children already in glasses are not 
screened and do not feature in the analysis of 
the data. Children are retested in school in the 
next term if the test is a borderline fail (0.225–0.3 
logMAR), or the orthoptist is not confident the 
VA is accurate. As long as the child was 
rescreened in the same academic year, their 
data were included in the analysis. Audit and 
feedback from the screenings are integrated 
with hospital patient records, orthoptists can 
access records of children they have screened, 
and formal feedback from the service is shared 
regularly.
School nurse delivered screening (SNDS)
This service is administered by the school nursing 
service based in the local authority, not the health 
authority, and feedback is patchier. The training is 
not orthoptist led or delivered, as is recommended 
by the UKNSC. Records held by the school nursing 
service are difficult to access by the health services 
due to data protection issues, and the health ser-
vices only feed back very basic data about referral 
outcomes (and no treatment outcomes) to the 
screening service.
The VA screen is part of other school entry 
health checks, and each nurse is based in a small 
number of schools, so they will test many fewer 
children’s VA per session and per year. There is 
no rescreen option, so all children not passing the 
screen are referred.
Children with mild deficits of vision (0.3logMAR 
in one eye and 0.2 in the other, 0.3 in both eyes, 0.4 
in one eye, and 0.3 in the other) are referred to local 
optometrists. For this study, we were unable to 
establish how many children were referred down 
this route, and this unknown number of children 
are lost to follow up.
For further details of procedures and differences 
between the services see the Supplemental File.
Methods
Outcomes from all referrals from children screened 
in the academic year 2018–19 were scrutinized 
from hospital records and data provided by the 
screening services. As it was an audit, Ethics 
Committee approval was not sought, but ethical 
principles were followed, such as early anonymiza-
tion of identifiable data, and involvement of stake-
holders. Data from the ODS was much more 
complete than the SNDS, both for structural rea-
sons and COVID-19-related difficulties in acces-
sing data.
Amblyopia was diagnosed on the first visit on 
return 6–8 weeks after being prescribed any glasses 
if the VA remained worse than 0.2 in one or both 
eyes in the absence of pathology. To try to capture 
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some idea of false negatives, which is not collected 
systematically, all orthoptists in the county were 
asked how many late-presenting children with 
reduced VA they had seen from the cohort who 
they considered to have been missed by the screen-
ing (not moved into the area later, presenting with 
mild, non-amblyopic myopia which was likely to 
have developed between the screening and referral, 
or failed offered diagnostic appointments after 
screening referral). The ODS service keeps the 
screening records for audit purposes so it was pos-
sible to confirm if a child had passed the original 
screen and orthoptists are encouraged to check.
Statistical analysis
Descriptive statistics were collected from available 
records of children screened, referred, followed to 
diagnosis, and followed to discharge. Where the 
data were reliable, calculations or best estimates 
were made for sensitivity, specificity, and positive 
predictive values for the target condition of VA 
worse than 0.2 in either eye.
Costs
Cost per screen included staff, administration, post-
age, screener travel, and any replacement equipment. 
In this pre-COVID-19 period, there were few dis-
posables. Costs reported were based on median pay 
points on national salary scales, travel at £0.25 per 
mile, national postage rates, published NHS appoint-
ment unit costs,7 payment made to local opticians to 
supply spectacles at a national voucher rate, occlu-
sion patches, and manufacturer’s listed equipment 
prices. At the time of analysis, the currency exchange 
rate was £1 = €1.12 = 1.25 USD. Any additional cost 
for the few children needing further pediatric 
ophthalmology opinions were not included.
Results
Orthoptist-led service
5878 children entered school in the year (for details 
see Table 1). 5839 (99.3%) were successfully 
screened, including. 202 (3.5%) children who were 
recalled for a second screening of equivocal results 
before passing successfully. The remainder had 
either special needs so were referred elsewhere 
(10), were sick or from traveling families, so were 
not in school on the testing day and were deferred 
to the next year (25). Four were untraceable.
199 (3.5%) children were referred from screen-
ing. 48 (24.1%) of these were lost to first follow up 
and a further 11 failed to attend during treatment, 
leaving 140 (70.4%) children traced to discharge on 
the audit date (July 2020).
Mean age at the new case visit was 5 years 
0.3 months, with a mean time from referral to 
reduced VA diagnosis of 42 days (range 8–122). 
Mean age at audit was 6 years 3 months and most 
had completed any active amblyopia treatment. 
Fifteen children were still being monitored early 
in 2020 when nonurgent appointments were can-
celed due to the COVID pandemic, so their final 
outcome is slightly delayed.
Of the 151 children whose screening results were 
followed up to diagnosis, 138 had confirmed 
reduced vision (91.4% true positive for reduced 
acuity). Thirteen (6.5%) were false positives, having 
failed the screening but had good equal vision and 
normal orthoptic assessment on their diagnostic 
visit, and were discharged.
It is not possible to be certain of the number of 
false negatives, but the poll of orthoptic department 
staff suggests it is never more than three per year. If 
this reasonable estimate is used, sensitivity for con-
firmed reduced VA and amblyopia of less than 0.2 
logMAR in one or both eyes was 98%, specificity 
was 99%. PPV was 91%.
129 children were refracted under cycloplegia 
and 126 were given spectacles. Two subsequently 
achieved normal VA without glasses, four were 
diagnosed with pathology.
Twenty children (14.9% of children with con-
firmed reduced VA) had refractive errors which 
would have passed the American Association of 
Pediatric Ophthalmology & Strabismus (AAPOS) 
refractive risk factor screening criteria (astigmatism 
>1.5 D, anisometropia >1.5 D, and hyperopia >3.5 
D)8 if they had been photoscreened, but had sig-
nificant reduced vision or amblyopia.
On the follow-up visit 6–8 weeks later 74% of the 
referrals reached better than 0.2 VA in each eye 
with glasses alone. Thirty-six (26%) of the children 
with confirmed reduced vision on their first visit 
were still amblyopic, but 17 normalized after 
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a longer period of “refractive adaptation.”9 So, of 
the 138 children with confirmed reduced vision on 
their first hospital visit, 79% improved with glasses 
alone or spontaneously (no glasses indicated on 
refraction).
Only 19 (13.7%) needed occlusion. Only one 
child (with strabismic and anisometropic amblyo-
pia) had final VA worse than 0.4 (0.7 logMAR) and 
eight others are still in the very final stages of 
treatment with 0.3 VA or better. Four children 
had subtle pathology on further investigation. The 
remainder of the referrals are either stable with no, 
or minimal, amblyopia and are discharged, or in 
the final stages of observation before discharge to 
their community optometrist.
The median number of visits for all children was 
3 (range 1–9). Of children still amblyopic on return 
with their first spectacles, the median number of 
visits was 5 (range 3–9), although 8 are still under 
supervision.
Costs (based on 2019–20 rates)
The total cost per screening test was £4.21 per child 
(Table 2). The cost of a hospital appointment to 
confirm reduced vision was £70 and the mean cost 
of a glasses voucher for all the children prescribed 
glasses was £46.59. The false positive screening 
Table 1. Numbers and percentages of children targeted by the orthoptist-led (ODS) and School Nurse Led (SNDS) screening services. n/ 
a = data not available.
Orthoptist (ODS) School nurse (SNDS)
n % n %
SCREENED
Elligible 5878 n/a
Present at screening 5839 n/a
Parents declined (% of elligible) 4 (0.01) n/a
Already in gls so not screened (% of elligible) 133 (2.3) n/a
Absent on first screen (% of elligible) 256 (4.5) n/a
Recalled (% of elligible) 202 (3.5) not done
Special needs so referred elsewhere/sick /traveler/to be screened next year/ 
untraceable (% of elligible)
39 (0.7) n/a
Total screened 5706 5630
REFERRALS
Referred (% of screened) 199 (3.5) 215 (3.8)
Followed to diagnosis (% of referrals) 151 (75.9) 173 (80.5)
Traced to final outcome or audit date (% of referrals) 140 (70.4) 170 (79.1)
Observed further without refraction then discharged (% of referrals) 0 14 (6.5)
True +ve for reduced VA (% followed to diagnosis) 138 (91.3) 83 (38.6)
True -ve (estimated) 5504 (96.5) 5405 (96.0)
True +ve for amblyopia after first glasses 36 (26.1) 25 (30.1)
False +ve for reduced VA 13 (6.5) 90 (41.9)
False -ve (later presenting low VA) (estimated) 3 (10)?
Cycloplegic refraction 129 99
Spectacles prescribed 126 89
Parents declined treatment/went elsewhere 5 4
Good VA with glasses from optometrist on new case visit (discharged) 6 5
VA on screening below 0.3 both eyes (%of referrals) 29 (14.6) 29 (13.5)
(of the above not myopia or myopic (so likely poor Near VA too)) 1 10
Low VA under AAPOS refractive risk factor referral threshold (% of children with 
low VA)
20 (14.5) 15 (18.1)
Age at follow up (years/months) 5 yrs 0mths 5 yrs 3mths
Age at full diagnosis (on return with glasses)(years/months) 5 yrs 2mths 5 yrs 5 mths
Mean delay from referral to diagnosis (weeks (range)) 6 weeks (1–17) 9 weeks (1–25)
Sensitivity for reduced VA 97.9% 95%CI 93.9%–99.6%
Specificity for reduced VA 99.8% 95%CI 99.6%–99.9%
Positive Predictive Value (PPV) for reduced VA 91.4% 95%CI 86.0%–94.8#% 53.2% 47.25%–59.07%
OUTCOMES
Followed to discharge or audit (% of referrals) 119 (59.8) 170 (79.1)
Pathology (% of referrals) 4 (2.0) 0 0
Needed occlusion after “refractive adaptation” (% of referrals) 19 (9.5) 11 (5.1)
Lost to full f/u (failed appointments or moved away after initial Dx) (% of genuine 
referrals)
80 (57.9) 25 (30.1)
Final VA worse than 0.2 in the worse eye 8 (4.0) 6 All ongoing
Final VA worse than 0.4 in the worse eye 1 (0.7) 2 All ongoing
Final VA worse than 0.2 in the better eye 0 0 0 0
In final stages of treatment (% of genuine referrals) 15 (7.5) 18 (21.7)
Median number of visits (all children) 3 Range 1–9 3 Range 1–6
Median number of visits (amblyopes) 5 Range 3–9 5 Range 3–6
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referrals cost the NHS £910 in total. The cost to full 
amblyopia diagnosis (screen + two hospital visits + 
spectacles) was £189.80 per child. The cost per child 
detected with confirmed reduced vision was 
£195.22, and per amblyope detected was £683.28.
School nurse delivered service
Data collected, and available, was much less com-
prehensive, and over the COVID lockdown some 
still is impossible to obtain (see Table 1).
About 5630 children were screened and 215 
(3.8%) were referred, so referral rates were similar. 
170 (79%) were followed to discharge or audit and 
11 failed to attend during treatment. 20% were lost 
to initial follow up. However only 83 referred chil-
dren had reduced vision confirmed at their new 
case visit (true positive for reduced acuity 48%). 
Seventy-three (34%) were clearly false positives 
(VA 0.1 logMAR or better in either eye) and were 
discharged after the first visit with normal VA 
(compared to 9% for the ODS). A further 14 (8%) 
had marginally reduced VA (0.125–0.2 logMAR in 
one or both eyes) felt to be due to immaturity or 
poor cooperation so were observed without refrac-
tion and were subsequently discharged without 
treatment as their VA improved to 0.1 logMAR or 
better. They were included as true or false positive 
numbers at the time an accurate diagnosis was 
made
An unknown number with mildly reduced vision 
(see Supplement) were advised to go to the optician 
and lost to follow up. From this cohort, which is of 
a similar size to the ODS, 138 children with 
confirmed reduced VA were referred by the ODS, 
but only 83 were referred by the SNDS, suggesting 
that many children were missed. If any with mildly 
reduced VA went to an optometrist, none were 
referred back for occlusion.
PPV was only 53%. Lack of data from optome-
trist referrals and the high false positive rate 
reduces our confidence in the accuracy of the 
data, and thus sensitivity and specificity, but they 
are likely to be lower in this service.
Seventy-four children with confirmed reduced 
vision were followed to discharge or the audit 
date, and 8 still being occluded at the onset of the 
2020 COVID lockdown, so final outcomes are not 
available. Only two children still have VA in the 
amblyopic eye of 0.4 or worse and both are still 
being treated.
Fifteen (18.5%) of children with reduced VA 
would have passed the AAPOS amblyopia risk fac-
tor referral threshold.
Costs
The actual screening costs cannot be identified 
because the screening is part of a general health 
screening, but they are carried out by personnel 
on similar pay bands, so are likely to be similar. 
The main difference in costs was in the higher costs 
of the false positive referrals. Although costs per 
genuine case and final VA outcomes for referred 
children were similar, the cost of the 73 false refer-
rals was nearly seven times that of the other service, 
while it is likely other children have been missed 
and so remain untreated.
Assuming similar screening costs, the cost per 
child with confirmed reduced vision seen at the 
hospital was £285.70 (46% more); and per 
amblyope detected was £948.09 (39% more), and 
this does not consider the cost and outcomes of the 
unknown number of children referred to local 
optometrists.
Discussion
A single visual acuity screen at 4–5 years, led and 
administered by orthoptists is unusual worldwide, 
when many countries screen repeatedly, or earlier, 
or use automated screening for refractive risk fac-
tors, rather than reduced VA itself.10,11 The 
Table 2. Actual costs at 2019–2020 published rates. Costs per 
child of screening and postreferral treatment of SNDS and ODS 
are likely to be similar.
COSTS (2019–2020 published rates) £ £
Exhange rate £1 = €1.12 = $1.25
Per screen (£) 4.21
Hospital appointment (£) 70
Per screen (£) 46.59
Box of patches (£) 8.75
Cost to amblyopia diagnosis (£) 189.8
Mean reduced VA treatment cost, diagnosis to 
discharge (£)
331.68




Cost to service per child with low vision (£) 195.22 285.70
Cost to service per child with amblyopia (£) 683.28 948.09
Total cost of false referrals (£) 910.00 6300.00
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UKNSC recommends that screeners should be 
orthoptists, or those trained by orthoptists, and 
this paper reports two ends of this spectrum – 
orthoptist screeners vs. minimal orthoptist input 
in two otherwise similar populations. The SNDS 
training is not supervised by orthoptists as is 
recommended. Data were much more accessible 
for the ODS and full audit and feedback more 
embedded, the importance of which is one of the 
messages of this paper. Tight audit has led to many 
small refinements of the ODS over the years, for 
example, recalling children in school, and going 
into the schools with a high proportion of disad-
vantaged or non-English speaking children later in 
the screening cycle to allow them a better chance of 
complying with testing because they had been in 
school longer.
A single screening by an orthoptist followed 
by orthoptist/hospital optometrist follow-up 
appears to be highly efficient and very low cost, 
both per screen, and per patient journey and per 
amblyope detected, compared to other 
alternatives.12–14 It is often assumed that highly 
skilled VA screening is more expensive,5 but 
these data suggest that it is not necessarily the 
case. The current UKNSC recommendation to 
not specifically test for strabismus, as is carried 
out in many countries11,15 seems supported. All 
children with significant newly diagnosed stra-
bismus also had reduced VA.
The SNDS resulted in many more false referrals, 
and therefore inefficient use of expensive hospital 
services, and probably more false negatives. The 
prevalence of refractive error is likely to be similar 
in both areas, so more children with reduced vision 
are probably missed. The ODS had a slightly lower 
referral rate (3.41% vs. 3.82%), and the local 
authority figures do not include the approximately 
0.65% of the cohort (using the ODS criteria) who 
might have been expected to be sent to local opti-
cians, not hospital services, so the true local author-
ity referral rate could have been nearer 4.5%.
The school nurses seem less expert in detecting 
genuine reduced vision. The UKNSC recommends 
that if orthoptists do not do the screening, they 
should train and monitor the screeners very care-
fully, but that is not the case for the SNDS described 
here. Orthoptists are particularly skilled in testing 
children’s vision, but they too had to learn. If 
orthoptists are not available, careful training to 
a gold standard, regular supervised practice, feed-
back, and audit seem to be the issue that defines the 
ability to test vision accurately, whoever does it.
A common argument for early or repeated 
screenings is that early treatment leads to better 
outcomes, and some cases of amblyopia can be 
prevented. Children start compulsory schooling at 
4–5 in England, so they are still well within the 
critical period; but still much older than propo-
nents of earlier screening would like.16 
Nevertheless, of the 126 children with confirmed, 
previously-undiagnosed reduced vision followed to 
discharge, all improved with treatment, which was 
usually glasses alone. 95% reached at least 0.2 
logMAR acuity (the lower 95% CI of normal acuity 
at age 66) in each eye, and a few more have slowly 
improving unilateral amblyopia. All children with-
out other pathology now have vision in at least one 
eye well within normal ranges and there is only one 
child with VA worse than 0.4 in an amblyopic eye 
who could suffer any significant functional disad-
vantage (e.g. unable to drive a car) if they were to 
lose their better eye. Children with strabismus 
either present earlier,17 would have been picked 
up by VA testing, or have small or intermittent 
strabismus with minimal amblyopia.
Photoscreening is often advocated because it can 
be carried out earlier, by less skilled testers. But it 
can result in high referral rates,18 more appoint-
ments from screen to discharge and other potential 
disadvantages (for review see Horwood et al.4) 
Importantly, in this study, 14–18% of children 
with reduced VA would have been missed by earlier 
photoscreening.
Some might argue that those with 0.2 final 
logMAR VA might have been ended up a line better 
if treated earlier,19 or that good acuity is necessary 
for general development in the toddler years, but 
none of these children’s parents had noticed any 
visual problem, and concerned parents had already 
sought treatment, so any disadvantage is likely to be 
small. Parents sometimes report improvements in 
behavior or performance after new glasses. This 
evidence is often anecdotal and very prone to pla-
cebo effects, but does need further research. There 
is little evidence that slightly blurred vision before 
school entry holds children back, or that minimal 
reduction in final best corrected acuity carries any 
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lifetime disadvantage. In a public health context 
such marginal gains may not be cost effective.
The main barrier to universal care was loss to 
follow-up, and with the SNDS, legal and practical 
barriers to data sharing. Data-protection laws pre-
vent health services contacting parents of screened 
children directly, so if a parent does not return their 
details, children cannot be sent appointments.
The main limitation of the study was data avail-
ability for the SNDS, but any COVID-related diffi-
culties in accessing some screening data do not 
account for the differences in outcomes or costs. 
Using estimates of false negatives is not ideal, but in 
the case of the ODS they do seem realistic because it 
is so rare to see any child that passed screening who 
presents later with amblyopia. The orthoptists gen-
erally check back to screening records and remem-
ber doing so.
A further limitation is that the analysis did not 
include the 2.3% of children who were wearing 
glasses on the day of screening. When setting up 
the service, it was decided not to test the vision of 
these children as it was being professionally mon-
itored elsewhere, and any amblyopia would have 
been detected and treated. This is an audit, not 
a prevalence study, and the focus of the service is 
the detection of previously undetected children at 
minimum cost and maximum efficacy. We also did 
not have the means to access these children’s diag-
nosis or prescription, and had no means to tell 
whether they would have passed the screening 
before they received the glasses (e.g. mild astigma-
tism or hypermetropia might be corrected by some 
optometrists). We were therefore unable to analyze 
their data further, and it does mean that the data 
should not be used as a precise measure of preva-
lence in the population.
The point at which amblyopia is diagnosed can 
vary. It could be on the day of refraction if VA does 
not improve with lenses, on the first visit on return 
with glasses or after full adaptation to glasses as 
recommended by many research studies.20,21 In 
this study, we chose the most common clinical 
definition (after 6–8 weeks of full-time glasses) 
and many children had achieved equal VA at this 
point.
It is possible that within the data there are differ-
ences between the communities, such as in socio- 
economic or ethnic disadvantage, that could 
explain some of the differences between the out-
comes. Although in the SNDS area there is one 
town with a very high proportion of South Asian 
and socio-economically disadvantaged families, it 
sits in an otherwise largely White British, affluent 
area, whereas in the ODS area the socio-economic 
and ethnic groupings are more widely spread. On 
average, the areas are broadly similar. While 
screening and follow-up may need to address spe-
cific at-risk groups,22 it was beyond the remit of this 
audit.
These results strongly support the UKNSC 
model as being highly cost effective. A single, accu-
rate screen by an experienced tester, at a site where 
high coverage and a retest is possible, and a joined- 
up service from screen to discharge seem key to 
success. Training, feedback, and audit allow refine-
ments to improve services.
If more resources are to be allocated, it might be 
better to use them to share best practice, improve 
training, audit, quality assurance, follow-up atten-
dance rates, feedback, and local and national data 
sharing, than add earlier, or more, screening events.
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